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Abstract
Background: Lysine acetylation is an important post-translational modification that plays a central role in eukaryotic
transcriptional activation by modifying chromatin and transcription-related factors. Human pregnancy-specific glycopro-
teins (PSG) are the major secreted placental proteins expressed by the syncytiotrophoblast at the end of pregnancy and
represent early markers of cytotrophoblast differentiation. Low PSG levels are associated with complicated pregnancies,
thus highlighting the importance of studying the mechanisms that control their expression. Despite several transcription
factors having been implicated as key regulators of PSG gene family expression; the role of protein acetylation has not been
explored.
Methodology/Principal Findings: Here, we explored the role of acetylation on PSG gene expression in the human
placental-derived JEG-3 cell line. Pharmacological inhibition of histone deacetylases (HDACs) up-regulated PSG protein and
mRNA expression levels, and augmented the amount of acetylated histone H3 associated with PSG 59regulatory regions.
Moreover, PSG5 promoter activation mediated by Sp1 and KLF6, via the core promoter element motif (CPE, 2147/2140),
was markedly enhanced in the presence of the HDAC inhibitor trichostatin A (TSA). This effect correlated with an increase in
Sp1 acetylation and KLF6 nuclear localization as revealed by immunoprecipitation and subcellular fractionation assays. The
co-activators PCAF, p300, and CBP enhanced Sp1-dependent PSG5 promoter activation through their histone acetylase
(HAT) function. Instead, p300 and CBP acetyltransferase domain was dispensable for sustaining co-activation of PSG5
promoter by KLF6.
Conclusions/Significance: Results are consistent with a regulatory role of lysine acetylation on PSG expression through a
relaxed chromatin state and an increase in the transcriptional activity of Sp1 and KLF6 following an augmented Sp1
acetylation and KLF6 nuclear localization.
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Introduction
Histone post-translational modifications have been shown to be
crucial for programmed gene expression during several events of
development in eukaryotes, including placental development and
functioning [1]. Histone covalent modifications include lysine
acetylation, lysine and arginine methylation, serine and threonine
phosphorylation, lysine ubiquitination, lysine sumoylation, and
glutamic acid poly-ADP-ribosylation [2]. Among them, histone
tail acetylation has been strongly correlated with transcriptional
activation [3]. This reversible modification is carried out by two
classes of enzymes, histone acetyltransferases (HATs) and histone
deacetylases (HDACs) [4]. cAMP-response-element-binding pro-
tein (CREB)-binding protein (CBP), p300, and p300/CREB-
binding protein-associated factor (PCAF) are among the several
HATs described so far. They act as transcriptional co-activators
with the capability to interact with a wide range of transcription
factors and integrate signals from different pathways, modify
histones, and remodel chromatin. Remarkably, HATs and
HDACs are not exclusively targeted towards histones. Some of
the nonhistone targets are transcription factors, chaperones, basal
transcriptional machinery components, signal transducers, hor-
mone receptors, and cytoskeleton proteins [5,6]. Dynamic
acetylation of histone and nonhistone proteins can be selectively
modulated by HDAC inhibitors (HDACis), thereby regulating
gene transcription by affecting chromatin assembly and/or
modifying protein–protein interactions, protein stability, DNA-
binding capability, transcriptional activity, and/or nuclear local-
ization of specific protein factors [7].
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The ubiquitously expressed transcription factors Sp1 and
Kru¨ppel-like factor 6 (KLF6) are well known molecular targets
of CBP, p300, and PCAF HAT function as well as of HDACs, in
several biological systems [8–12]. Sp1 and KLF6 have been
described as important regulators for normal placental develop-
ment and formation [13,14] and they have also been associated
with the transcriptional control of placental specific genes such as
17 b-hydroxysteroid dehydrogenase [15], human chorionic gonadotropin b
subunit (hCGb) [16], and pregnancy-specific glycoprotein 3 and 5 (PSG3
and PSG5) [17–19].
PSGs constitute the major group of secreted proteins synthe-
sized by the placental syncytiotrophoblast, reaching 200–400 mg/
L in maternal serum at the end of normal gestation [20]. Although
their functions have not been fully established, several lines of
evidence suggest they are essential for the maintenance of a
normal pregnancy. Indeed, low PSG levels are associated with a
poor pregnancy outcome [21,22]. In addition, they promote
alternative macrophage activation, which correlates with a shift
from inflammatory Th1- to anti-inflammatory Th2-mediated
immunological responses in vitro and in vivo [23–25]. Current data
also suggest that PSGs play an important role in the process of
vasculature establishment at the maternal-fetal interface ensuring
feto-placental blood supply [26,27]. The measurement of PSG
serum levels was proposed as a useful biomarker to monitor and
diagnose gestational pathologies more than thirty years ago
[28,29]. Human PSGs are encoded by 11 genes clustered within
700-kilobases on chromosome 19q13.2, which share above 90%
nucleotide sequence identity [30]. PSG gene promoters are highly
homologous lacking common minimal consensus promoter
sequences such as TATA-box, initiator elements or long pyrim-
idine-rich GC regions [31,32]. We have previously demonstrated
that PSG5 promoter activity is largely dependent on a core
promoter element (CPE, CCCCACCC) conserved in all PSG
genes [33]. This sequence mediates PSG5 transcriptional activa-
tion by Sp1 and KLF6 [18,19]. In addition, KLF4 and Retinoid X
receptor alpha, as well as the RARE and GABP consensus-binding
sites located at the proximal promoter are involved in PSG gene
transcription [17,34,35]. However, the remarkable increase in
PSG biosynthesis associated with villous trophoblast differentiation
strongly suggests the contribution of other regulatory mechanisms.
The aim of this work was to explore whether lysine acetylation
of both histone and specific transcription factors is involved in PSG
gene expression control. Here, we demonstrate that PSG gene
expression is markedly up-regulated when HDACs are inhibited.
Gene activation correlates with a higher level of acetylated histone
H3 associated with the PSG 59 flanking regions. In addition, PSG5
induction by Sp1 and KLF6 transcription factors is potentiated by
TSA treatment, which also increases Sp1 acetylation and KLF6
nuclear localization. Finally, Sp1-mediated activation of the PSG5
promoter is further induced by CBP, p300, and PCAF in a HAT-
dependent manner, whereas CBP and p300 exert their function as
KLF6 co-activators through a mechanism independent of their
HAT activity.
Materials and Methods
Culture Conditions
Human placental-derived JEG-3 cell line (ATCC, HTB-36),
obtained from the American Type Culture Collection (ATCC,
Rockville, USA), was maintained in DMEM supplemented with
10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml
streptomycin (Invitrogen), at 37uC in 5% CO2. For treatments,
cells were plated at a density of 16106 cells/10 cm plates. After
overnight incubation, cells were treated for 18 h with several
concentrations of NaBu, TSA (Sigma) or with their respective
solvent vehicles, H2O or 0.015% DMSO.
MTT Assay
After establishing the adequate cell density for viability/
cytotoxicity assay, 16104 JEG-3 cells/well were plated in a 96-
well plate. Twenty four hours later, cells were incubated with
NaBu or TSA. After treatment, 10 ml (5 mg/ml) of 3-(4, 5-
dimethlthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT)
was added to each well and cells were incubated for 2.5 h at
37uC. Then, the medium was carefully removed, formazan
crystals were dissolved for 5 min in 100 ml of DMSO/well, and
absorbance was measured at 570 nm. Cell viability was established
as 100% in the control condition where the cells were incubated
with H2O or 0.015% DMSO.
Reverse Transcription and Quantitative Real-time PCR
Total RNA from 6-well plates was extracted with TRIzol
(Invitrogen) reagent, as recommended by the manufacturer. One
microgram of extracted RNA, 25 ng of random hexamers
(Invitrogen), 20 U of RNAsin (Promega), and 200 U of murine
leukemia virus reverse transcriptase (Promega, Madison, WI,
USA) were used to synthesize cDNA.
Total PSG transcript levels were quantified by real-time RT-
PCR in an ABI 7500 Sequence Detection System (Applied
Biosystems) using the reaction conditions and primer pair
previously described [34]. The primers recognize all the PSG
gene family member transcripts and the amplicons obtained are of
identical length. Data are presented as fold change in PSG gene
expression normalized to peptidylprolyl cis-trans isomerase A
(PPIA) expression and relative to non-treated cell cultures selected
as the calibrator condition. Each sample was analyzed in triplicate.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP analyses were carried out according to the ChIP assay kit
(Upstate Biotechnology) manufacturer’s instructions with minor
modifications. Briefly, cells were cross-linked with 1% formalde-
hyde at room temperature for 10 min and subsequently, the cross-
linking was blocked with 125 mM glycine for 5 min. Cells were
lysed in lysis buffer supplemented with protease inhibitor cocktail
(Sigma), followed by sonication (Sonics Vibra Cell, USA), and pre-
clearing with salmon sperm DNA/protein A agarose. The
histone/DNA complexes were incubated overnight at 4uC with
2 mg of polyclonal anti-acetyl-H3 (Upstate Biotechnology) anti-
body. As immunoprecipitation specificity controls, cell lysates were
incubated with 2 mg of polyclonal anti-PSG (A0131, Dako) or
without antibody. The immunocomplexes were centrifuged at
12000 rpm and supernatants were precipitated with salmon sperm
DNA/protein A agarose at 4uC for 4 h. Complexes were serially
washed and then, DNA was purified using 200 ml of 10% p/v
Chelex 100 resin (BIORAD). The samples were boiled for 10 min,
treated with proteinase K (10 mg/ml) at 55uC for 1 h, and boiled
for additional 10 min to inactivate the protease activity. Samples
were centrifuged at high speed and the supernatants were
recovered.
The amplification reactions were carried out under not
saturating conditions using 0.25 mM of each For and Rev primer,
annealing temperature of 55uC and 5 mM Mg2+ concentration.
The primers employed and amplicon sizes are indicated in Table 1.
A transcriptionally active euchromatic region corresponding to
a GAPDH promoter sequence and a PSG5 coding region (+234/
+533) were used as acetyl H3-DNA immunoprecipitation positive
and negative controls, respectively.
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Reporter Constructs
The recombinant promoter-luciferase constructs containing
different sizes of PSG3 and PSG5 promoters and their 59 regulatory
regions were obtained as previously described [34]. The XB3-luc
reporter construct was obtained by amplification of the PSG3
regulatory region (positions -1463/249) and cloning into the NheI
and BglII sites of the pGL3 basic vector (Promega). The
CPEmutUB5luc reporter plasmid was obtained from the UB5-
luc construct by PCR-directed mutagenesis of the CPE element (59
CCCCACCCAT 39 to 59 CCCCgatatc 39).
Transient Transfection and Luciferase Activity Assay
For promoter activity assays, JEG-3 cells seeded at a density of
16105 per well in 24-well plates were cultured for 24 h and
transfected using the optimized conditions described in reference
[34]. Medium was completely replaced 4 h post-transfection and
cells were treated with 150 nM TSA for 18 h before harvesting.
For co-transfection experiments JEG-3 cells were transfected with
2 ml Lipofectamine 2000 (Invitrogen) and 850 ng of total DNA
using 500 ng of the indicated PSG reporter plasmid and 150 ng of
each expression vector in the combinations indicated in figure
legends. The expression vectors pCI-PCAF Flag and pCI-
PCAFDHAT Flag [36], pCMV-CBP HA and pCMV-CBPDHAT
HA were gently supplied by Dr. Greer, pCMVb-p300 HA and
pCMVb-p300 DI1485AL HA were a gift of Dr. Hecht [37], and
pXJ-KLF6 [38] and pCMV-Sp1 were kindly provided by Dr.
Bocco. The corresponding empty vectors (pCMV, pCI and pXJ-
41) were used in control transfections and to adjust the total
amount of DNA when necessary. After 48 h post-transfection, cells
were collected, lysed in lysis buffer (Promega), and luciferase
activity was measured using the Luciferase Assay System
(Promega) on a GloMax-Multi Detection System (Promega).
Luciferase activity in each sample was normalized to protein
levels determined by the Bradford method.
Immunofluorescence Staining
JEG-3 cells were cultured on cover slips using complete
medium with the addition of TSA or NaBu as described above.
Immunofluorescence assays were performed as previously
reported [19]. The following polyclonal rabbit primary anti-
bodies were used: anti-PSG (A0131, Dako) 1/100, anti-KLF6
(R-173, Santa Cruz Biotechnology) 1/50, anti-Sp1 (H225, Santa
Cruz Biotechnology) 1/200, and anti-acetyl-H3 (Upstate) 1/500.
Cells were incubated with green Alexa Fluor 488-conjugated
donkey anti-rabbit IgG (Molecular Probes, Inc., Eugene, OR) at
1/720 final dilution. Nuclei were counterstained with Ho¨echst
33258 for 15 min. The antibody incubations were performed in
a humidity chamber for 1 h at 37uC. Cells were examined
under an epifluorescence microscope (Nikon Eclipse TE2000-U,
USA) and images were collected with appropriate filters at the
magnification indicated in figure legends.
Western Blot Analysis
Cells were harvested in Laemmli sample buffer after 48 h of
HAT co-activator overexpression or after 18 h of TSA
treatment and then subjected to protein expression analysis.
Western blot assays were performed as described earlier [34].
The following primary antibodies were employed: polyclonal
rabbit anti-Flag (Sigma-Aldrich) 1/2500, monoclonal mouse
anti-HA (Abcam) 1/1000, polyclonal anti-acetyl-H3 (Upstate) 1/
6000, polyclonal anti-Sp1 1/2000, monoclonal mouse anti-
KLF6 (clone 2c11, whose specificity was previously determined
[38]) 1/10000, polyclonal rabbit anti-PSG (A0131, Dako) 1/
500, monoclonal mouse anti-GAPDH (4300 Ambion) 1/1000,
polyclonal goat anti-Ku80 (sc-1484 Santa Cruz) 1/1000, and
monoclonal mouse anti-b-actin (Sigma-Aldrich) 1/2000.
Culture Supernatant Protein Detection
To determine PSG protein secretion in culture supernatants,
JEG-3 cells were grown and treated as described before. The
supernatants of DMSO- and TSA-treated cells were recovered
after centrifugation at 10000 rpm for 10 min at 4uC, and
subjected to western blot analysis to detect secreted PSG protein.
Ponceau staining was used as loading normalizer.
Table 1. Primer sequences used in conventional PCR for ChIP assays and their corresponding amplification product sizes.
Gene Primer name Sequence (59- 39) Product size (bp)
PSG locus
PSG -178 For attgctagcgagaggaggggacagagaggt 129 bp
PSG -49 Rev agagctcgagagaaacttcctgagcacggc
PSG locus
PSG -970 For ccaggctccccctcctgcgtctcaa 487 bp
PSG -551 Rev ttaaccccattgtgctgtgggtgagctgtgtg
PSG locus
PSG -1463 For ctgctccatctagactgttctctggg 448 bp
PSG -977 Rev caggggttcagagcctggagagatt
GAPDH
GAPDH For tactagcggttttacgggcg 166 bp
GAPDH Rev tcgaacaggaggagcagagagcga
PSG5
PSG5 coding region For caagtcacgattgaagccct 300 bp
PSG5 coding region Rev tactcctctagtcctatcacctcg
doi:10.1371/journal.pone.0055992.t001
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Immunoprecipitation Assay
JEG-3 cells were transiently transfected with 620 ng pCMV-
Sp1 or pXJ-KLF6. Thirty hours later, cells were treated with or
without 150 nM TSA for 18 h. Cells were washed with cold 1X
PBS, harvested in 500 ml non-denaturizing lysis buffer (20 mM
Tris-HCl pH 8, 1% NP40, 10% glycerol, 137 mM NaCl, 2 mM
EDTA, 1 mM PMSF, and protease inhibitor cocktail), and then
incubated at room temperature for 30 min with rotation. Protein
concentration in the supernatant was measured using the Bradford
assay. Two hundred micrograms of total protein extracts from
each cell condition were incubated overnight at 4uC in an orbital
rotor with 6 mg of rabbit anti-Sp1 antibody or 6 mg of anti-KLF6
antibody mix (2 mg polyclonal R-173 and 4 mg monoclonal clone
2c11) previously cross-linked to 2 ml of protein G Mag Sepharose
beads (GE Healthcare Life Sciences). The immunocomplexes were
washed once with TBS buffer (50 mMTris-HCl pH7.5, 150 mM
NaCl), eluted in 0.1 M glycine-HCl buffer (pH 2.5), and then
neutralized with 1 M phosphate buffer (NaPO4, pH 8). Laemmli
sample buffer (5X) was added to each eluted fraction and boiled
for 5 min. Proteins were then separated by SDS-PAGE, trans-
ferred onto nitrocellulose Hybond-ECL (Amersham Bioscience)
membranes, blocked with 5% non-fat milk in PBS-Tween 20
(0.1%), and probed with polyclonal anti-acetyl lysine antibody
(Millipore, AB3879) at 1/1500 dilution. The membranes were
stripped and re-probed with anti-Sp1 (1/2000) or anti-KLF6
(monoclonal clone 2c11, 1/10000) antibodies. Bands were
revealed by enhanced chemiluminescence detection system
(SuperSignal West Pico; Pierce) and visualized by exposing to
Kodak T-Mat G/RA films.
Subcellular Fractionation
JEG-3 cells treated with 150 nM TSA or DMSO were washed
three times with 1X PBS and incubated for 15 min on ice with
500 ml lysis buffer (50 mM Tris-HCl pH 7.5, 137.5 mM NaCl,
10% glycerol, 1 mM sodium vanadate, 50 mM NaF, 10 mM
Na4P2O7, 5 mM EDTA, and protease and phosphatase inhibitor
cocktails) containing 0.5% Triton X-100. The lysates were
centrifuged at 13000 rpm for 15 min at 4uC to obtain the
membrane/cytoplasmic fraction in the supernatant. The nuclear
pellets were rinsed once with lysis buffer, then resuspended in
150 ml 0.5% SDS-lysis buffer, and sonicated for 5 seconds. Lysates
were pre-cleared by centrifugation at 13000 rpm for 15 min at
4uC. Laemmli sample buffer (5X) was added to nuclear and
membrane/cytoplasmic fractions, boiled for 10 min, and then
subjected to western blot assay. The presence of Ku80 and
GAPDH exclusively in the nuclear and membrane/cytoplasmic
fractions, respectively, confirmed the cell fractionation success. In
addition, they were used as loading control of each subcellular
fraction.
Statistical Analysis
Pair-wise comparison between groups was evaluated with a 2-
tailed Student’s t test or one-way ANOVA between multiple
groups followed by Fisher’s test to determine a statistical difference
(Infostat Software, http://www.infostat.com.ar). A value of
p#0.05 was considered statistically significant.
Results
PSG Protein and mRNA Expression is Stimulated by
HDAC Inhibitors
To investigate whether acetylation is involved in the activation
of PSG gene expression we used the human JEG-3 cell line. These
cells retain features of placental trophoblasts, synthesize several
placental hormones and enzymes, and represent an established
model for trophoblast studies [34,39,40]. JEG-3 cells were treated
with the HDACis TSA or NaBu, at a range of concentrations that
did not alter cell viability (Fig. 1A). Under these experimental
conditions, PSG transcript levels increased when compared to
non-treated control cultures, as determined by real time RT-PCR
(Fig. 1B). The induction of PSG mRNA was much higher with
TSA than NaBu, which is in line with the reported stronger
inhibition of HDACs by TSA [41]. In addition, enhanced PSG
protein staining was detected by immunofluorescence after 18 h of
incubation with either NaBu (Fig. 1C) or TSA (Fig. 1D). The
highest induction of PSG protein and mRNA levels was observed
at 150 nM TSA, condition that was selected for conducting the
following experiments. In this condition, PSG protein levels
(Fig. 1E) increased and PSG secretion (Fig. 1F) was also up-
regulated as revealed by western blot detection in total cell lysates
and culture supernatants, respectively.
TSA Treatment Increases Acetylation of Histone H3
Associated with PSG Gene Promoters
HDACis have been described to induce a global increase of
histone acetylation in the nucleus [42], however, it is well
documented that their effects on gene expression are not global
but they rather alter the expression of a few specific genes (1–7%)
with a comparable number of repressed and derepressed genes
[43–45]. High throughput analysis have demonstrated that acetyl
H2AK7, H3K9, H3K14, H3K18, H4K5, and H4K12 are found
principally enriched in the 59 regulatory region of active genes,
where they create an accessible chromatin domain. Particularly,
acetylation of histone H3K9/14 has been proposed as a signature
of active transcription [46–48]. Therefore, we investigated
whether the increase in PSG expression correlated with an
augmented level of acetylated H3K9/14 at the 59 regulatory
region of PSG genes. First, we confirmed a global increase of
acetylated H3 level in JEG-3 cells treated with 150 nM TSA
compared to control cells by immunofluorescence and western
blot analysis carried out using the specific anti-acetyl-H3 antibody
that recognizes acetyl H3K9 and K14 (Fig. 2A and B). Next, ChIP
assays were performed on chromatin isolated from TSA-treated or
control JEG-3 cells immunoprecipitated with the anti-acetyl-H3
antibody. The amplification of three conserved DNA fragments in
the promoter and 59 regulatory region of all PSG genes clearly
demonstrated that they were enriched in acetylated histone H3 in
TSA-treated cells (Fig. 2C and D). As expected, no or faint
amplification was detected for the PSG5 coding sequence, as well
as for all the samples incubated with the non-related antibody or
without antibody. Instead, the GAPDH promoter sequence was
clearly amplified in the anti-acetyl-H3 immunoprecipitated DNA
(Fig. 2C).
In summary, these results indicate that TSA treatment
correlates with an increased acetylation of histone H3 associated
with the PSG gene promoter and 59 proximal regulatory regions.
TSA Treatment Markedly Induces PSG3 and PSG5
Promoter Activities
As mentioned before, HDAC inhibition can modulate gene
expression not only through the induction of a local chromatin
conformation change, but also modifying the function of
nonhistone proteins. Thus, to further investigate the relationship
between HDAC inhibition and transcriptional up-regulation of
PSG genes, we examined whether TSA could activate PSG3 and
PSG5 promoters. JEG-3 cells were transfected with luciferase
reporter plasmids containing different fragments of the 59
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regulatory regions and then, they were treated with TSA. A
notable increase in the reporter activity of all PSG3 (Fig. 3A and
B) and PSG5 (Fig. 3C and D) promoter constructs was detected.
PSG3 reporter constructs reached activities up to 6-7-fold higher
in cells cultured with TSA than controls (Fig. 3B), while UB5luc
and PB5luc constructs were activated 30.7- and 12.4-fold
(Fig. 3D), respectively, in the presence of TSA compared to
the control condition. These data strongly suggest that TSA
induces PSG3 and PSG5 expression at the transcriptional level
and reveal that proximal promoter sequences are potentially
involved in the response to HDAC inhibition.
TSA Enhances Sp1- and KLF6-induced PSG5 Promoter
Activation through the CPE Element
The CPE motif is an important cis-regulatory element present in
all PSG gene proximal regulatory sequences. This motif is involved
in PSG5 promoter activation and is recognized by Sp1 and KLF6,
as previously demonstrated by luciferase reporter, EMSA and
supershift assays [18,19,49]. Therefore, we analyzed whether TSA
could modulate Sp1 and KLF6 effect on PSG5 promoter activity.
In the absence of this HDACi (DMSO, control condition) the
UB5luc construct activity was induced near 1.5- and 2.0-fold by
Sp1 and KLF6 overexpression, respectively (Fig. 4A, lanes 2 and 3
vs 1), confirming previous results [18,19]. UB5luc reporter activity
Figure 1. Total PSG protein and mRNA expression is stimulated by HDAC inhibitors. A) JEG-3 cells were cultured in the presence of the
indicated concentrations of NaBu (white bars), TSA (grey bars) or vehicle alone (0, control condition) for 18 h. MTT assay was used to determine cell
survival. Results represent the mean6 SEM of three independent experiments performed in sixtuplicates and are shown as percentage respect to the
non-treated cultures established as 100%. No statistically significant differences (p.0.05) compared to the control condition were detected. B) Total
PSG mRNA levels were determined by real time RT-PCR (ABI 7500, Applied Biosystems) in JEG-3 cells cultured in the presence of the specified
concentrations of NaBu (white bars) or TSA (grey bars) and in control cultures (0). Results were normalized to PPIA and expressed according to the 2–
DDCt method using as calibrator the mRNA level obtained from the corresponding control cultures. Data are presented as mean 6 SEM of four
independent experiments performed in triplicates. Significant differences were set at * p#0.05, respect to control. C, D) Immunofluorescence of PSG
(green, left panels) and nuclear staining with Ho¨echst (blue, middle panels) in JEG-3 cells after treatment with the indicated amounts of NaBu (C), TSA
(D) or vehicle (control). Right panels: merged images. Bar = 10 mm. Original magnification: 1000X. E, F) Western blot detection of PSG protein in JEG-
3 cell total extracts (E) and secreted PSG levels in culture supernatants (F) after 150 nM TSA or DMSO exposure. b-actin (for PSG cellular content) and
Ponceau staining (for secreted PSG) were used as loading normalizers. A representative experiment of two independent assays is shown.
doi:10.1371/journal.pone.0055992.g001
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was increased almost 60-fold in cells transfected with Sp1 or KLF6
and treated with TSA compared to control basal condition
(Fig. 4A, lanes 5 and 6 vs 1) and near 2-fold respect to the
induction provoked by TSA alone (Fig. 4A, lanes 5 and 6 vs 4).
These observations are consistent with a potentiation of Sp1- and
KLF6-dependent transactivation of the UB5luc reporter in the
presence of TSA. In contrast, reporter activity of the CPEmutU-
B5luc construct was not stimulated by Sp1 or KLF6 transcription
factors (Fig. 4B, lanes 2 and 3 vs 1), and the synergistic activation
by TSA was lost (Fig. 4B, lanes 5 and 6 vs 4). Although TSA was
able to augment the reporter activity of the CPEmutUB5luc
construct (Fig. 4B, lane 4 vs 1), the wild type promoter construct
was induced near 31-fold while the CPE mutated one was
stimulated only about 10-fold (p#0.05). These results indicate that
TSA-mediated PSG5 promoter stimulation partially depends on
the CPE motif, suggesting that other regulatory sequences located
in the 2254/249 PSG5 promoter region are also involved.
In summary, these data indicate that TSA potentiates Sp1- and
KLF6-induced PSG5 promoter activation through a functional
CPE binding site.
TSA Stimulates Sp1 Acetylation and KLF6 Nuclear
Localization
Sp1 and KLF6 transcription factors have been described as
molecular targets of lysine acetylation/deacetylation [8–12]. Thus,
we decided to evaluate whether TSA modulates Sp1 and KLF6
function through modifications in their acetylation, localization,
and/or expression in trophoblast cells. To this end, JEG-3 cells
were treated with TSA or DMSO (control) for 18 h and the
endogenous transcription factor expression and localization were
analyzed. Western blot analysis revealed a reduction in Sp1 level
in JEG-3 cells treated with TSA, whereas KLF6 whole-cell content
was not affected (Fig. 5A). Epifluorescence imaging microscopy
suggested that nuclear Sp1 localization was maintained, while
Figure 2. TSA treatment increases acetylation of histone H3 associated with PSG gene promoters. JEG-3 cells were exposed to 150 nM
TSA or 0 nM TSA (DMSO 0,015%, non-treated controls) for 18 h. A) Epifluorescence immune detection of acetyl H3 (Ac-H3) protein (green, left panels)
and Ho¨echst counterstaining (blue, middle panels). Merged images are shown on the right panels. Scale bar: 10 mm. Original magnification: 1500X. B)
Western blot assay to detect whole cell content of acetyl H3 (Ac-H3) in protein extracts from JEG-3 cells treated with DMSO or TSA. b-actin protein
was used for normalization of protein loading. A representative experiment of three independent assays is shown. C) ChIP analyses. TSA- and DMSO-
treated JEG-3 cells were fixed with formaldehyde. DNA-protein complexes were sonicated and immunoprecipitated using anti-acetyl-H3 (Ac-H3), anti-
PSG (as non related antibody, NR) or without antibodies (No Ab). Input and recovered DNA samples were amplified by conventional PCR employing
primer pairs flanking positions 2178/249, 2970/2551, and 21463/2977 of the regulatory region of PSG genes (positions are indicated relative to
the PSG5 gene). A PSG5 coding sequence and a transcriptionally active euchromatin region of the GAPDH promoter were used as negative and
positive immunoprecipitation controls, respectively. Results are representative of duplicated PCR reactions from two independent ChIP assays. D)
Densitometric quantification of amplified products of the PSG gene regulatory regions normalized to the corresponding input is shown after
subtraction of No Ab and NR amplification. Results are presented as mean 6 SD and referred as fold change respect to DMSO control condition
(arbitrarily defined as 1).
doi:10.1371/journal.pone.0055992.g002
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KLF6 nuclear localization increased in TSA-treated compared to
control cells (Fig. 5B and Fig. 5C). Subcellular fractionation assays
confirmed these results. They showed a similar nuclear and a
lower cytoplasmic/membrane content of Sp1, and a clear nuclear
enrichment of KLF6 accompanied by a decrease in its cytoplas-
mic/membrane content after TSA exposure (Fig. 5D).
In order to analyze whether the acetylation state of Sp1 and/or
KLF6 is modulated by HDAC inhibition, JEG-3 cells were
independently transfected with each expression plasmid and then,
treated or not with TSA. Immunoprecipitation assays with Sp1 or
KLF6 antibodies followed by western blot analysis with an anti-
acetyl lysine antibody revealed an increase in Sp1 acetylation in
response to TSA, while the acetylated-KLF6 level remained
unchanged (Fig. 5E).
Altogether, these results suggest that Sp1- and KLF6-mediated
activation of PSG5 promoter could be enhanced by TSA through
an increase in both Sp1 acetylation and KLF6 nuclear localiza-
tion.
PSG5 Promoter is Regulated by Transcriptional Co-
activators with HAT Activity
CBP, p300, and PCAF proteins are common co-activators for a
variety of transcription factors [50,51]. They have intrinsic HAT
activity thus they also mediate acetylation of histone and
nonhistone proteins. Furthermore, they can bind and/or acetylate
Sp1 and KLF6 [9–12,52,53]. For these reasons, we next explored
the hypothesis that these co-activators modulate Sp1- and KLF6-
mediated transcriptional activation of PSG. To this end, expression
vectors encoding the native or HAT-deficient versions of CBP,
PCAF, and p300 co-activators were individually co-transfected
together with the UB5luc reporter construct in the presence of
overexpressed Sp1 or KLF6. Expression of each co-activator
construct was confirmed by western blot assays (data not shown).
As shown in Figure 6A, Sp1 stimulation of the UB5luc construct
was further increased by p300, CBP, and PCAF (lanes 2, 4, and
6vs 1) but not by the HAT-deficient variants (lanes 3, 5, and 7 vs 1).
On the other hand, p300 and CBP, but not PCAF, were able to
further induce the KLF6-dependent UB5luc construct activation
(Fig. 6B, lanes 2, 4, and 6 vs 1), and HAT-defective p300 and CBP
constructs co-activated the PSG5 promoter to the same extent that
their wild type versions (Fig. 6B, lane 3 vs 2 and lane 5 vs 4).
Altogether, these results suggest that CBP, p300, and PCAF
modulate PSG5 expression through a direct acetylation of Sp1
and/or basal machinery components, while CBP and p300
potentiate KLF6-mediated PSG5 transcriptional activation by a
mechanism independent of their HAT function.
Discussion
Despite the relevance of PSG genes for mammalian gestation,
the comprehension of the molecular mechanisms that govern their
biosynthesis in placental cells is far away from complete. The
importance of histone modifications associated with placental-
specific gene expression and hence proper placenta differentiation
and functioning [54] prompted us to explore the relationship
between lysine acetylation and PSG gene regulation. In this report
Figure 3. Induction of PSG3 and PSG5 promoter activity in TSA-exposed JEG-3 cells. Scheme of reporter constructs bearing the 59
regulatory region of PSG3 (A) and PSG5 (C) genes. Circles depict the CPE regulatory element. Luciferase activity was determined in JEG-3 cells
incubated with 150 nM TSA (grey bars) or DMSO (white bars). Results are expressed as relative luciferase activities (RLA) referred to the promoter
activity of NB3luc (B) or UB5luc (D) construct in DMSO control cultures, arbitrarily set as 1. Data are shown as mean 6 SEM of four independent
experiments performed in triplicates. Italic bold numbers represent fold increase in luciferase activity of each construct in TSA-exposed cells relative
to the control ones. Data were subjected to analysis of variance (one-way ANOVA) followed by Fisher’s test to determine significant statistical
differences (p#0.05). Different letters on the right side of each bar indicate statistically different values.
doi:10.1371/journal.pone.0055992.g003
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we present the first evidence that PSG gene expression can be
regulated by lysine acetylation involving histone and nonhistone
target proteins. We found that PSG transcripts and proteins
increase after treatment of placental JEG-3 cells with HDAC
inhibitors. TSA not only induces PSG biosynthesis, but more
significantly stimulates PSG secretion. HDACis are known to skew
the acetylation balance towards an hyperacetylation state affecting
chromatin assembly and/or modulating nonhistone protein
function [7]. Our results indicate that TSA enhances PSG
expression through a direct effect on transcription, increasing
the amount of acetylH3K9/14 associated with PSG promoters.
Additionally, it stimulates an augmented Sp1 acetylation and
KLF6 nuclear localization that correlate with transcriptional
activation of the PSG5 promoter. Growing evidences point to a
relevant role of lysine acetylation in placental-specific gene
expression; however the upstream signals that regulate histone
or transcription factor acetylation have not yet been identified. For
instance, the expression of the trophoblast transcription factor
GCM1 depends on deacetylase- and acetylase-mediated regula-
tion [55]. Placental increased expression of maspin, a tumor
suppressor gene, is associated with a transcriptionally active
chromatin characterized by a high level of H3K9 acetylation [56].
Kumar et al. detected an augmented H3K9/14 acetylation and
decreased H3K9 methylation linked to the transcriptional
induction of the human CYP19 gene during the differentiation of
trophoblast cells [57]. Additionally, transcriptional activation of
the hGH genes has been linked to unique roles not only for HAT,
but also for histone methyltransferase co-activator complexes, and
to an expansive histone H3 and H4 acetylation of the locus in
syncytium, where the four placental hGH genes are expressed at
the highest levels [58]. Collectively, these data support our findings
suggesting that lysine acetylation may contribute to the remarkable
increase of PSG gene expression in trophoblast cells. In addition,
altogether these observations are in line with the proposal that
modulation of HDAC and HAT activities through still unknown
upstream biological signals is required for trophoblast differenti-
ation.
Synergistic activation of PSG5 promoter by Sp1 and TSA
suggests that Sp1 acetylation may increase its binding to the CPE
element and/or may expose interaction sites to other transcrip-
tional activator proteins to enhance the expression of PSG genes.
Synergistic activation was also observed by KLF6 and TSA.
However, we could not detect any change in the KLF6 acetylation
state, but we did observe its clear redistribution into the nucleus.
Different scenarios could explain its nuclear enrichment. First,
modifications in the activity of a putative cytoplasmic KLF6
partner or a competitor protein could result in KLF6 cytoplasmic
release and redistribution to the nucleus. In line with this
possibility, recent findings have demonstrated that cytoplasmic c-
Src protein interacts with KLF6 and have suggested that KLF6
and estrogen receptor alpha are competitors for c-Src [59].
Second, TSA-induced hyperacetylation could affect other modi-
Figure 4. TSA enhances Sp1- and KLF6-induced PSG5 promoter activity through the CPE element. Cells co-transfected with the UB5luc
(A) or CPEmutUB5luc (B) construct and the Sp1 (lanes 2 and 5), KLF6 (lanes 3 and 6) or empty (lanes 1 and 4) expression plasmids were cultured in the
presence of DMSO (lanes 1–3) or 150 nM TSA (lanes 4–6). Data represent relative luciferase activity (RLA) referred to that of each reporter construct
co-transfected with the corresponding empty vector (EV) and treated with DMSO. Results are shown as mean 6 SEM of triplicates of two to four
independent assays. Different letters on the bars indicate statistically different values (p#0.05, Fisher test following one-way ANOVA). CPE binding
sequence (uppercase bold letters) and mutated nucleotides (lowercase letters) are depicted.
doi:10.1371/journal.pone.0055992.g004
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fying enzyme functionality, such as kinases, which in turn would
modify KLF6 allowing its nucleo-cytoplasmic shuttling. Support-
ing this notion, it has been widely described that HDACis can
modulate different kinase signaling pathways. For instance, Cao
and coworkers [60] have established that acetylation of MAPK
phosphatase-1 blocks the MAPK signaling cascade after TSA
exposure. TSA has also been demonstrated to inhibit ERK
activation in human renal tubular epithelial cells [61]. Addition-
ally, NaBu has been shown to produce down-regulation of ras/
raf/MEK/ERK signaling pathway [62]. Several other reports
have documented that HDACis can inhibit PI3K/Akt pathway in
diverse cell types [63–65]. A third possibility is that the increased
nuclear KLF6 localization is due to a raise in its protein expression
level. In this sense, it has been reported that KLF6 overexpression
in JEG-3 cells results in an enhanced nuclear localization [19].
However, we can rule out this explanation since KLF6 whole cell
content was not affected after TSA treatment. Further studies
should be performed to identify the precise molecular mechanisms
underlying the KLF6 nuclear re-localization induced by HDAC
inhibition in trophoblast cells.
The transcriptional co-activators p300, CBP, and PCAF play
important roles in multiple biological events including cell growth
and differentiation. They enhance transcription by physically
linking different regulatory molecules, and their intrinsic HAT
activity facilitates transcriptional activation through direct acety-
lation of histone and nonhistone proteins [66,67]. Herein, we
demonstrated that PCAF, p300, and CBP enhanced Sp1-
dependent PSG5 promoter activation through their HAT func-
tions. On the contrary, we found that p300 and CBP acetyltrans-
ferase function was dispensable for sustaining co-activation of
PSG5 promoter by KLF6. Our findings are in line with results of
Suzuki et al. [68], who demonstrated that p300 binds to and
acetylates the Sp1 DNA binding domain, but not that of KLF6.
Interestingly, other Sp/KLF family members have been also
described to interact differentially with these co-regulators.
Particularly, CBP/p300 and PCAF function as Fetal Kru¨ppel-
like factor 2 co-activators although only PCAF requires its HAT
activity, whereas CBP in a HAT-dependent way, but neither
PCAF nor p300, acts as Erythroid Kru¨ppel-like factor co-activator
on gamma-globin promoter in erythroid cells [69]. Further studies of
how co-activators modulate the activity of transcription factors of
the same family may improve our understanding of tissue and
developmental stage-specific expression not only of PSG, but also
of other important placental specific genes.
Recent data propose that the final outcome of KLF6 expression
depends on the particular cell context, endogenous or external
signals, interaction with specific transcriptional partners and/or its
subcellular distribution [70]. KLF6 has been shown to be
Figure 5. TSA stimulates Sp1 acetylation and KLF6 nuclear localization. A) Protein extracts prepared from JEG-3 cells exposed to TSA or
DMSO (control condition) for 18 h were subjected to western blot analysis using anti-Sp1 (upper panel), anti-KLF6 (middle panel), and anti-b-actin
(lower panel) antibodies. Representative blots are shown of at least three independent experiments with similar results. B, C) Immunofluorescence
analyses of endogenous Sp1 and KLF6 (green signal, left panels) distribution in DMSO-cultured JEG-3 cells (upper panels) and TSA-treated cells (lower
panels). Nuclei were counterstained with Ho¨echst dye (blue signal, middle panels). Merged images are shown on the right panels. The images
presented are representative of three independent experiments. Scale bar = 10 mm. Original magnification= 1000X. D) Western blot analysis of the
endogenous Sp1 and KLF6 protein content detected in the cytoplasmic/membrane (lanes 1 and 2) and nuclear (lanes 3 and 4) fractions of JEG-3 cells
treated with DMSO (lanes 1 and 3) or TSA (lanes 2 and 4). GAPDH and Ku80 protein levels were used as loading and fractionation controls. One
representative experiment of four independent assays with consistent results is shown. E) Immunoprecipitation and western blot assays were
performed to determine the acetylation state of overexpressed Sp1 and KLF6 in JEG-3 cells treated or not with TSA. Whole cell lysates were first
precipitated with anti-Sp1 or a mix of anti-KLF6 antibodies and then subjected to western blotting with anti-acetyl lysine antibody (Ac-Lys). The same
amount (30 mg) of immunoprecipitated proteins were loaded in each lane. The blots of one representative of two different experiments are shown.
The ratio of acetylated (Ac) to total Sp1 or KLF6 of each independent experiment is indicated below each band.
doi:10.1371/journal.pone.0055992.g005
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acetylated and to interact with CBP and PCAF in prostate cancer
cells in vivo, contributing to the up-regulation of p21WAF1/cip1 gene
expression [11]. Interestingly, Li et al. identified that KLF6
interacts with HDAC3 to achieve Dlk1 promoter repression,
leading to the induction of key regulators of adipocyte differen-
tiation [71]. Nevertheless, in the context of trophoblast cells little is
known about the biochemical requirements for KLF6 transcrip-
tional activity and the complexes through which KLF6 regulates
target gene expression. As mentioned above, we demonstrated that
KLF6 is acetylated in JEG-3 cells and its acetylation state
remained unmodified after TSA exposure. Moreover, considering
that CBP and p300 functioned as KLF6 co-activators in a manner
independent of their HAT activity, it is possible to postulate that
KLF6 acetylation is achieved by acetyltransferases other than
CBP, p300, and PCAF in this cell context.
Despite PSG gene members share a high degree of sequence
identity, including their close promoter sequences, disparity
expression level has been observed between different human PSGs
[34,72,73]. It has been proposed that subtle nucleotide variation in
PSG gene promoters allows for differential expression [74].
However, a direct correlation between similar PSG transcript level
in syncytiotrophoblast and sequence conservation of putative
regulatory elements could not be established [34]. In the present
study we found that PSG3 and PSG5 promoter constructs were
differentially activated following HDAC inhibition, suggesting that
acetylation might contribute to differential PSG gene expression.
In summary, we provided for the first time evidence that lysine
acetylation regulates PSG expression in concert with Sp1 and
KLF6 transcription factors. HDAC inhibition induced PSG
transcription and protein synthesis correlating with a higher level
of acetylated histone H3 associated with the proximal regulatory
region of PSG genes. We identified different ways to achieve a
synergistic PSG5 promoter activation through TSA and Sp1 or
TSA and KLF6. While Sp1 is a direct molecular target of
acetylation, KLF6 exhibits a nuclear enrichment after HDACi
exposure. Finally, we defined that co-activators with HAT
function cooperate in PSG transcriptional activation through both
Sp1 and KLF6 transcription factors employing mechanisms with
differential dependence of their HAT activity. Due to the high
nucleotide identity between the different PSG genes, it is possible to
hypothesize that other family members share similar regulatory
mechanisms to the ones identified here for PSG5.
Altogether, our findings lead to a better understanding of the
molecular basis that control PSG expression and open avenues to
pursue future research on the molecular mechanisms of PSG gene
activation during placental differentiation.
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Figure 6. Effect of HAT co-activators on PSG5 promoter activation mediated by Sp1 and KLF6. JEG-3 cells were transfected with the
UB5luc plasmid and the expression vectors coding for Sp1 (A) or KLF6 (B) alone (lane 1) or together with either wild-type (lanes 2, 4, and 6) or HAT-
deficient (lanes 3, 5, and 7) versions of p300 (light grey bars), CBP (dark grey bars) or PCAF (black bars). Data are shown as relative luciferase activity
(RLA) to that of JEG-3 cultures co-transfected with the corresponding empty vectors defined as 1 (dashed line). Results are presented as mean 6 SD
of one representative experiment of two independent assays performed in triplicates, with consistent results. Statistical differences (p#0.05) were
identified using two-sided Student’s t-test. * depicts statistically different values compared to that of the culture co-transfected with the
corresponding empty vectors. { represents statistically different values compared to that of the culture co-transfected with the wild type version of
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